UC Davis Eye Center tests experimental gene therapy for wet age-related macular degeneration (AMD)

Ophthalmologists at UC Davis Health used an experimental gene therapy last month to treat a patient with wet age-related macular degeneration, or wet AMD. Wet AMD is a leading cause of vision loss among older adults. Glenn Yiu, a professor of ophthalmology at UC Davis Health, is the principal investigator for the new clinical trial.

Blinding Eye Disease Is Strongly Associated With Heart Disease and Stroke

Patients with a specific form of age-related macular degeneration (AMD), a leading cause of blindness in the United States, are at significant risk for cardiovascular disease and stroke, according to new research from New York Eye and Ear Infirmary of Mount Sinai.

New Procedure Improves Vision In Those With Macular Degeneration

A new corneal laser procedure for vision improvement in patients with late-stage, dry or wet age-related macular degeneration and other retinal disorders allows patients to regain several lines of useful vision, to read again, and to experience improved quality of life

Scientists identify a new drug target for dry age-related macular degeneration

Scientists at Sanford Burnham Prebys Medical Discovery Institute have shown that the blood protein vitronectin is a promising drug target for dry age-related macular degeneration (AMD), a leading cause of vision loss in Americans 60 years of age and older. The study, published in the Proceedings of the National Academy of Sciences (PNAS), also holds implications for Alzheimer’s and heart disease, which are linked to vitronectin.

Artificial Intelligence Algorithm Can Rapidly Detect Severity of Common Blinding Eye Disease

A new artificial intelligence (AI) algorithm developed by researchers at New York Eye and Ear Infirmary of Mount Sinai (NYEE) can rapidly and accurately detect age-related macular degeneration (AMD), a leading cause of vision loss in the United States.